10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Androgen Receptor (Phospho-S213) Antibody

Catalog # AP60535

Product Information

Application	WB, IHC, IF/IC
Primary Accession	P10275
Reactivity	Human, Mk
Host	Rabbit
Clonality	Polyclonal
Calculated MW	99188

Additional Information


Gene ID	367
Other Names	DHTR; NR3C4; Androgen receptor; DIHCydrotestosterone receptor; Nuclear receptor subfamily 3 group C member 4
Target/Specificity	KLH-conjugated synthetic phosphopeptide corresponding to residues surrounding S213 of human Androgen Receptor protein. The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500) IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500) IF/IC~~N/A
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information


Name	AR
Synonyms	DHTR, NR3C4
Function	Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Cellular Location	Nucleus. Cytoplasm Note=Detected at the promoter of target genes

	(PubMed:25091737) Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
Tissue Location	[Isoform 2]: Mainly expressed in heart and skeletal muscle.


Images




Western blot analysis of Androgen Receptor (Phospho-S213) expression in HEK293T (A), A549 (B), H1792 (C) whole cell lysates. (Predicted band size: 99; 110 kD; Observed band size: 99 kD)




Immunohistochemical analysis of Androgen Receptor (Phospho-S213) staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.



Immunofluorescent analysis of Androgen Receptor (Phospho-S213) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.



Immunohistochemical analysis of Androgen Receptor (pS213) staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.



Direct ELISA antibody dose-response curve using Anti-Androgen Receptor (Phospho-S213) Antibody. Antigen (Phosphopeptide and non-phosphopeptide) concentration is 5 ug/ml. Goat Anti-Rabbit IgG (H&L) - HRP was used as the secondary antibody, and signal was developed by TMB substrate.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.